TF and cancer: The TF MYC is encoded by a proto-oncogene and classified to the basic helix-loop-helix leucine zipper (bHLH-LZ) family, while its overexpression is a hallmark of cancer development and derives, among others, as an outcome of diverse genetic backgrounds (e.g., duplications, or somatic mutations) [89,108] or epigenetic mechanisms [5], which stabilize its in vivo abundance.